

## **Certificate of analysis**

#### SFC180-01-01

Operator: Galbha Duggal

Supervisor: Zam Cader

Signature: Dade


Date: 13/08/15

Date: 12/02/2016 Source of fibroblasts and reprogramming information

- SF180 from Glostrup Hospital, Denmark 15/08/2014
- Reprogrammed at UOXF WIMM
- Reprogrammed on 17/10/2014 at passage 4
- Cytotune v2 WP3 SOP10


# Viability post-thaw and Morphology according to SOP19 passage 17

- Cell count immediately post-thaw 1.34 x 10<sup>6</sup>
- Viability immediately post-thaw 90.5%
- Photo at 24h & day 4 post-thaw (scale bar = 100μm):



### Sendai clearance: according to WP3 SOP15 undetectable at passage 17





+ control SFC180-01-01 SFC856-03-07 SFC856-03-08 SFC856-03-04

Product sizes: Actin 92bp; SeV 181bp; SeV KOS 528bp; SeV-Myc 532bp; SeV-Klf 410bp;

# Mycoplasma Test: According to MycoAlert Lonza LT07-318 undetectable at passage 17

Sample	Passage Number	Initials	Reading 1	Reading 2	Ratio/Status
+ ve control			54	5829	107.94
- ve control			105	77	0.73
SFC180-01-01	p17	GD	50	14	0.28


Results:

Ratio 0 - 0.999 negative for mycoplasma


Ratio 1 – 1.3 Borderline Result (retest required)


Ratio above 1.3 positive for mycoplasma

## Flow cytometric analysis according to WP3 SOP 20 and 21 passage 17



#### NANOG:





# SNP analysis according to WP3 SOP Preparation of DNA and RNA samples for Illumina arrays

- Passage 17
- Identity to parent fibroblasts confirmed
- Karyotype abnormalities: none detected
- For details and raw data see StemDB